Caldera Therapeutics is a biotech company developing bispecific antibodies like CLD-423 for IBD and inflammatory diseases. Discover innovative autoimmune treatments today.
Investors 1
Mentions in press and media 6
| Date | Title | Description |
| 30.03.2026 | Qyuns Therapeutics-B (02509) 2025 Revenue Surges Over 4-Fold; Adjusted Profit Reaches Approximately RMB356 Million, Turning a Profit Year-on-Year | TAIZHOU, China, March 30, 2026 /PRNewswire/ -- Qyuns Therapeutics-B (02509) announced its 2025 annual results. Revenue amounted to approximately RMB807 million, representing a 4.08-fold year-on-year increase. Gross profit reached approximat... |
| 16.01.2026 | Amperon Secures Samsung Ventures Backing for Global AI Energy Forecasting Growth | Amperon, a leader in AI-powered energy forecasting, recently secured a significant investment from Samsung Venture Investment Corporation. This undisclosed funding fuels global expansion and advanced product development. Amperon’s AI soluti... |
| 14.01.2026 | Caldera Therapeutics Launches With $112.5 Million And Doses First Subjects In Phase 1 Trial Of CLD-423 | Caldera Therapeutics, a clinical-stage biotechnology company developing a first-in-class bispecific antibody for inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases, launched with $112.5 million in total capital... |
| 14.01.2026 | Amperon Receives Investment From Samsung Ventures | Amperon, a Houston, TX-based provider of AI-powered energy forecasting and analytics solutions, received an investment from Samsung Venture Investment Corporation.
The amount of the deal was not disclosed.
The company intends to use the fun... |
| 14.01.2026 | Caldera Therapeutics Launches with $112.5M in Total Capital | Caldera Therapeutics, Inc., a Cambridge, MA-based clinical stage biotechnology company, launched with $112.5M total capital raised.
The amount consisted of a $75M Series A round from Atlas Venture, LAV and venBio, and most recently a $37.5M... |
| - | Caldera Therapeutics | “Caldera Therapeutics is a biotech company developing bispecific antibodies like CLD-423 for IBD and inflammatory diseases. Discover innovative autoimmune treatments today.” |
Reviews 0
